title: Cardiovascular effects produced by microinjection of angiotensins and angiotensin antagonists into the ventrolateral medulla of freely moving rats.
abstract: In this study we determined the cardiovascular effects produced by microinjection of angiotensin peptides [Angiotensin-(1-7) and Angiotensin II] and angiotensin antagonists (losartan, L-158,809, CGP 42112A. Sar1-Thr8-Ang II, A-779) into the rostral ventrolateral medulla of freely moving rats. Microinjection of angiotensins (12.5-50 pmol) produced pressor responses associated to variable changes in heart rate, usually tachycardia. Unexpectedly, microinjection of both AT1 and AT2 ligands produced pressor effects at doses that did not change blood pressure in anesthetized rats. Conversely, microinjection of Sar1-Thr8-Ang II and the selective Ang-(1-7) antagonist, A-779, produced a small but significant decrease in MAP an HR. These findings suggest that angiotensins can influence the tonic activity of vasomotor neurons at the RVLM. As previously observed in anesthetized rats, our results further suggest a role for endogenous Ang-(1-7) at the RVLM. The pressor activity of the ligands for AT1 and AT2 angiotensin receptor subtypes at the RVLM, remains to be clarified.
authors.affiliation: Departamento de Fisiologia e Biofisica, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
authors.forename: M A
authors.initials: MA
authors.lastname: Fontes
authors.forename: M C
authors.initials: MC
authors.lastname: Martins Pinge
authors.forename: V
authors.initials: V
authors.lastname: Naves
authors.forename: M J
authors.initials: MJ
authors.lastname: Campagnole-Santos
authors.forename: O U
authors.initials: OU
authors.lastname: Lopes
authors.forename: M C
authors.initials: MC
authors.lastname: Khosla
authors.forename: R A
authors.initials: RA
authors.lastname: Santos
mesh_terms: D000803:Angiotensin I; D000804:Angiotensin II / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology*; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects*; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology; D019808:Losartan; D008297:Male; D008526:Medulla Oblongata / Q000187:drug effects / Q000502:physiology*; D008845:Microinjections; D009842:Oligopeptides / Q000008:administration & dosage / Q000494:pharmacology; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013777:Tetrazoles / Q000008:administration & dosage / Q000494:pharmacology; D013997:Time Factors
chemical_list: C092006:7-Ala-angiotensin (1-7); D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D007093:Imidazoles; D009842:Oligopeptides; D010446:Peptide Fragments; D013777:Tetrazoles; D000804:Angiotensin II; C060894:CGP 42112A; C014805:angiotensin II, Sar(1)-Thr(8)-; D000803:Angiotensin I; C118790:angiotensin I (1-7); D019808:Losartan